Combined 3D-QSAR, molecular docking and dynamics simulations studies to model and design TTK inhibitors

Noureen Ashraf1, Asnuzilawati Asari2, Numan Yousaf1

  • 1Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan.

Frontiers in Chemistry
|November 21, 2022
PubMed

Insights

This study developed new computational models to design improved inhibitors targeting Tyrosine Threonine Kinase (TTK), a key protein in cell division and cancer. The designed compounds show promise as lead candidates for cancer drug development.

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Molecular Biology

Background:

  • Tyrosine threonine kinase (TTK) is crucial for the spindle assembly checkpoint (SAC), ensuring accurate chromosome segregation.
  • Overexpression of TTK is linked to various human cancers, making it a validated drug development target.
  • Existing TTK inhibitors provide a basis for designing more effective therapeutic agents.

Purpose of the Study:

  • To design novel, more active inhibitors of Tyrosine Threonine Kinase (TTK) using 3D-QSAR.
  • To explore structure-activity relationships for 1H-Pyrrolo[3,2-c] pyridine derivatives targeting TTK.
  • To computationally validate the binding affinity and stability of newly designed TTK inhibitors.

Main Methods:

  • Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA) were employed for 3D-QSAR modeling.
  • Ligand and structure-based alignment, along with various partial charge models (e.g., MMFF94), were utilized.
  • Molecular docking, molecular dynamics (MD) simulations, and MM/PBSA free energy calculations were performed for validation.

Main Results:

  • Highly predictive CoMFA (q² = 0.583) and CoMSIA (q² = 0.690) models were developed using MMFF94 charges and structure-based alignment.
  • Electrostatic, steric, hydrogen bond acceptor (HBA), hydrogen bond donor (HBD), and hydrophobic fields were identified as key in the structure-activity relationship.
  • Designed compounds demonstrated stable binding to the TTK active site and reasonably good binding affinity through simulations and free energy calculations.

Conclusions:

  • The developed 3D-QSAR models provide a reliable framework for designing potent TTK inhibitors.
  • Newly designed compounds exhibit promising characteristics as lead compounds for TTK inhibitor optimization.
  • This study offers a computational strategy for advancing the development of novel anti-cancer therapeutics targeting TTK.

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
929
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
13.1K
Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.6K
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
740